Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology
Can-Fite Secures Japanese Patent Allowance for Namodenoson's Anti-Obesity Technology
Can-Fite Publishes Peer-Reviewed Scientific Article Demonstrating the Broad Therapeutic Potential of Piclidenoson and Namodenoson
Can-Fite to Present Late-Stage Clinical Pipeline and Licensing Opportunities at BIO International Convention 2026
Can-Fite Reports Positive Clinical Observation in Phase 2a Pancreatic Cancer Study and Highlights Namodenoson's RAS Signaling Inhibition Mechanism
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson’s Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
Scientific Publication of Can-Fite and Vetbiolix Validates Piclidenoson's Potential in the Multi-Billion Dollar Canine Osteoarthritis Market
Following Positive Phase 2a Pancreatic Cancer Data, Can-Fite Advances Namodenoson into Phase 2b Combination Study with Immunotherapy
Can-Fite Reports Positive Phase 2a Data with Namodenoson in Pancreatic Cancer; 35% of Patients Remain on Therapy, Including One Beyond 16 Months
Can-Fite's Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026
Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient
Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance
CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study
Can-Fite's Namodenoson Successfully Meets Primary Endpoint in Phase 2a Pancreatic Cancer Study
Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy
Can-Fite: Patient with Decompensated Liver Cirrhosis Successfully Undergoes Liver Transplantation Following Treatment with Namodenoson
Can-Fite Completes Patient Enrollment in Phase 2a Pancreatic Cancer Study of Namodenoson
Can-Fite BioPharma Stock Scheduled to Reverse Split on Monday, January 5th (NYSE:CANF)
Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change
Can-Fite Provides Update on Clinical and Financial Status
Can-Fite’s Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference
Can-Fite's CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil
Can-Fite Reports H1 2025 Financial Results and Clinical Update
Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone
Can-Fite Announces Up To $15.0 Million Public Offering
Breakthrough Study from UCLA Demonstrate Can-Fite's Piclidenoson as a Treatment for Vascular Dementia
Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients
Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares
Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market
Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson
Can-Fite Innovative Publication: Namodenoson in Liver Cancer Treatment Alongside with Cardiac, Liver, and Neurological Benefits
Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on February 25
Can-Fite BioPharma to Present the Namodenoson Anti-Obesity Effect at BIO CEO & Investor Conference 2025
CanFite Biopharma (CANF) Upgraded to Strong Buy: Here's What You Should Know
Recognition of the American Society of Clinical Oncology (ASCO) of the Liver Protective Effect of Can-Fite's anti-Cancer Drug Namodenoson
Bears are Losing Control Over CanFite Biopharma (CANF), Here's Why It's a 'Buy' Now
60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial
Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia
Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with Piclidenoson
FDA Grants Orphan Drug Designation to Can-Fite's Namodenoson for Pancreatic Cancer
Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of Health
Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
OS Therapies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds
Can-Fite Provides Namodenoson Patent Update
Join Can-Fite's Exclusive Live Investor Webinar and Q&A Session on August 8
Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic Cancer